Posts

Sufficiency at the priority date: A study protocol is not "the same" as a therapeutic effect invention (T0883/23)

Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy

UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21

Stretching the cheese: Contradictory evidence for a purported technical effect relied on for inventive step (T 0629/22)

Petition for review filed in referring decision to G2/21 (T 0116/18)

Crystallising the interpretation of G 2/21 (T 1989/19)

Clarity on the interpretation of G2/21 from the referring Board (T 0116/18)